Atopic Dermatitis
Conditions
Brief summary
Atopic Dermatitis is a chronic non contagious disease that causes itchy, inflamed skin. The purpose of this study is to evaluate the safety and efficacy of topical AS101 ointment for the treatment of Atopic dermatitis.
Detailed description
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, affecting 10-20% of children and 2% of adults worldwide. The mechanism of AD is still not completely understood, but the disorder appears to result from the complex interaction between immunological responses, various susceptability genes, defects in skin barrier function, host and environmental factors and infectious agents. AS101 is a non toxic potent immunomodulator that has been shown to have beneficial effects in diverse pre clinical and clinical studies. Recently, AS101 has shown efficacy and safety in the treatment of mild to moderate Psoriasis which shares with AD a related immunological mechanism along with the AS101 ability to decrease the level of interleukins known to be involved ith the pathogenesis of AD.
Interventions
DRUGAS101 ointment
Twice daily topical application
Sponsors
BioMAS Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosed Atopic Dermatitis for at least 6 months prior to enrollment. * Diseased Body surface area (BSA) ≤ 20%. * Male and Female ≥ 18. * Adequate general health. * Signed Informed consent form by the patient or his/her legal guardian. * Patient must be able and willing to comply with all protocol requirements.
Exclusion criteria
* Patient who is unable to provide fully informed consent. * Pregnant of breast-feeding females. * Concomitant dermatologic or medical condition(s) which may interfere with the patient's response evaluation. * Evidence of an infection in the targeted zones. * Known sensitivity to any of the drug component. * Immunocompromised patients. * Concomitant medications such as: * Topical corticosteroid within 2 weeks prior to Day 1 visit; * Systemic steroids and immunosuppressants within 1 month prior to Day 1 visit; \*Systemic anti-histamines and antibiotics within 2 weeks prior to Day 1 visit; \*Phototherapy within 4 weeks prior to Day 1 visit; * Anticipated exaggerated exposure to sunlight during the whole treatment period and 4 weeks prior to Day 1 visit.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified SCORAD index | within 6 weeks treatment and 4 weeks follow up |
Secondary
| Measure | Time frame |
|---|---|
| Remission period | within 4 weeks post treatment completion |
Countries
Israel
Outcome results
None listed